ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

daprodustat

Also written as “GSK1278863”, “Daprodustat” and “Daprodustat (GSK1278863)”.

Its studies are mostly in Anemia · Diabetic Foot · Peripheral Vascular Diseases · Tendon Injuries, led by 2 companies.

Drug pageGSK1278863: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 2, 201633 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline320 open or runningphase 3since Jun 2, 2016Jun 16, 2011none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 3since Dec 10, 2025Dec 10, 2025May 2027phase 3 · NCT07300111

Also a collaborator on its studies: Q2 Solutions, Quintiles, HemoCue and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Jun 16, 2011.

  1. Feb 19, 2015Phase 1 study in AnemiaNCT02371603 · 70 enrolled · United States
  2. Jun 9, 2015Named daprodustatINNProposed as its International Nonproprietary Name in WHO's List 113 · before, GSK1278863
  3. Feb 11, 2016Phase 2 study in AnemiaNCT02689206 · 103 enrolled · United States, Canada, Germany and more
  4. Jun 2, 2016Phase 3 study in AnemiaNCT02791763 · 355 enrolled · Japan
  5. Jul 8, 2016Phase 3 study in AnemiaNCT02829320 · 28 enrolled · Japan
  6. Aug 19, 20162 phase 3 studies in AnemiaNCT02876835, NCT02879305
  7. Jan 20, 2017Phase 2 study in AnemiaNCT03029247 · 105 enrolled · United States
  8. Jan 20, 2017Phase 3 study in AnemiaNCT03029208 · 312 enrolled · United States, Argentina, Australia and more
  9. Jul 17, 20172 phase 1 studies in AnemiaNCT03239522, NCT03223337
  10. Jan 8, 20182 phase 3 studies in AnemiaNCT03409107, NCT03400033
  11. Feb 20, 2018Phase 2 study in AnemiaNCT03446612 · 6 enrolled · United Kingdom
  12. Mar 1, 2018Phase 2 study in AnemiaNCT03457701 · 15 enrolled · United States
  13. Apr 4, 2018Phase 1 study in AnemiaNCT03493386 · 64 enrolled · Japan
  14. Nov 18, 2020Phase 1 study in AnemiaNCT04640311 · 259 enrolled · United States
  15. Jan 4, 2023Phase 3 study in AnemiaNCT05682326 · 4 enrolled · Japan, South Korea

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447

Studies

All 32 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05682326Anemia · Japan, South Korea3CompletedOct 18, 20244
NCT04640311Anemia · United States1CompletedMay 18, 2021259
NCT03493386Anemia · Japan1CompletedJun 9, 201864
NCT03457701Anemia · United States2CompletedJul 5, 202215
NCT03446612Anemia · United Kingdom2TerminatedMay 29, 20196
NCT03409107Anemia · United States, Argentina, Australia and more3CompletedOct 7, 2020614
NCT03400033Anemia · United States, Argentina, Australia and more3CompletedJun 19, 2020407
NCT03223337Anemia · United States1CompletedAug 20, 201837
NCT03239522Anemia · United Kingdom1CompletedNov 28, 20176
NCT03029247Anemia · United States2CompletedJul 9, 2020105
NCT03029208Anemia · United States, Argentina, Australia and more3CompletedSep 24, 2020312
NCT02879305Anemia · United States, Argentina, Australia and more3CompletedNov 9, 20202,964
NCT02876835Anemia · United States, Argentina, Australia and more3CompletedApr 19, 20213,872
NCT02829320Anemia · Japan3CompletedMay 16, 201728
NCT02791763Anemia · Japan3CompletedOct 26, 2018355
NCT02689206Anemia · United States, Canada, Germany and more2CompletedJan 25, 2017103
NCT02371603Anemia · United States1CompletedAug 12, 201570
NCT02293148Anemia · United States1CompletedMar 10, 201561
NCT02231190Tendon Injuries · United States1CompletedJun 12, 201526
NCT02243306Anemia · United States1CompletedMay 10, 20178
NCT02075463Anemia · United States2TerminatedMar 16, 201615
NCT02019719Anemia · Japan2CompletedAug 6, 201497
NCT01977573Anemia · United States, Australia, Canada and more2CompletedMay 1, 2015252
NCT01977482Anemia · United States, Australia, Canada and more2CompletedFeb 1, 2015216
NCT01920594Surgical Procedures · United States, Canada2CompletedOct 8, 201457
NCT01831804Diabetic Foot · United States1CompletedFeb 10, 201765
NCT01673555Anemia · United States1CompletedNov 19, 201249
NCT02135848Peripheral Vascular Diseases · United States2CompletedNov 1, 201146
NCT01587924Anemia · United States, Canada, Denmark and more2CompletedMay 27, 201380
NCT01587898Anemia · United States, Canada, Germany2CompletedMay 7, 201372
NCT01406340Anemia · United States1TerminatedAug 31, 201322
NCT01376232Anemia · India1CompletedDec 20, 201023

How it is read

Names in the registry

  • “GSK1278863”, 15 entries
  • “Daprodustat”, 9 entries
  • “Daprodustat (GSK1278863)”, 2 entries
  • “Daprodustat tablets”, 1 entry
  • “1 to 4 mg tablets of GSK1278863”, 1 entry

Codes read as this program: GSK1278863.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.